Search results for "B-Cell"

showing 10 items of 279 documents

Intrasinusoidal bone marrow infiltration: a possible hallmark of splenic lymphoma.

1996

A particular type of lymphomatous bone marrow infiltration defined as intrasinusoidal and occuring in seven patients with splenomegaly and mild to moderate thrombocytopenia is reported. Immunocytochemistry highlighted the intrasinusoidal pattern and showed a mature B-cell phenotype. Four patients underwent splenectomy and a diagnosis of splenic marginal cell lymphoma was made. The disease course seems to be chronic and quite indolent. All patients are alive and well ; follow-up ranges from 2 to 42 months. The value of bone marrow biopsy as a primary diagnostic tool in splenic marginal zone lymphomas is discussed.

AdultMalePathologymedicine.medical_specialtyHistologyLymphoma B-Cellmedicine.medical_treatmentSplenectomySpleenPathology and Forensic MedicineImmunophenotypingSinusoidBone MarrowBiopsymedicineHumansAgedmedicine.diagnostic_testbusiness.industryLymphoma Non-HodgkinSplenic NeoplasmsBone Marrow ExaminationGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistrymedicine.anatomical_structureImmunohistochemistryFemaleBone marrowSplenic diseaseSplenic LymphomabusinessHistopathology
researchProduct

MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central …

2021

Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity and specificity of myeloid differentiation primary response (88) (MYD88) L265P mutation (mut-MYD88) and interleukin-10 (IL-10) in cerebrospinal fluid (CSF) of both patients with newly diagnosed (n = 36) and relapsed (n = 27) PCNSL and 162 controls (118 CNS disorders and 44 extra-CNS lymphomas). The concordance of MYD88 mutational status between tumour tissue and CSF sample and the source of ILs in PCNSL tissues were also investigated. Mut-MYD88 was assessed by TaqMan-based polymerase chain reac…

AdultMalePathologymedicine.medical_specialtyLymphomaBiopsyConcordanceinterleukin-10diffuse large B-cell lymphomaMutation MissenseCentral Nervous System Neoplasms03 medical and health sciencesprimary CNS lymphoma0302 clinical medicineCerebrospinal fluidhemic and lymphatic diseasesBiopsyBiomarkers TumorTaqManmedicineHumansdiffuse large B-cell lymphoma interleukin-10 interleukin-6 MYD88 L265P mutation primary CNS lymphomaProspective cohort studyAgedmedicine.diagnostic_testbusiness.industryinterleukin-6Primary central nervous system lymphomaHematologyMiddle Agedmedicine.diseaseInterleukin-10Neoplasm ProteinsLymphomaMYD88 L265P mutationAmino Acid Substitution030220 oncology & carcinogenesisMyeloid Differentiation Factor 88FemalebusinessDiffuse large B-cell lymphoma030215 immunologyBritish Journal of Haematology
researchProduct

Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diff use large B-cell lymphoma: comparison b…

2015

Summary Background Since 2001, the World Health Organization classification of tumours of haematopoietic and lymphoid tissues and the International Classification of Diseases for Oncology (third edition) have improved data collection for lymphoma subtypes in most European cancer registries and allowed reporting on the major non-Hodgkin lymphoma subtypes. Treatment of non-Hodgkin lymphoma has changed profoundly, benefiting patients with follicular lymphoma or diffuse large B-cell lymphoma. We aimed to compare dynamics of cancer mortality in patients with follicular lymphoma or diffuse large B-cell lymphoma in five large European areas using data for survival from the largest number of collab…

AdultMalePathologymedicine.medical_specialtyPediatricsAdolescent[SDV]Life Sciences [q-bio]Follicular lymphomaAutopsyNOminimum clinical recommendations03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinemedicinefollow upHumans030212 general & internal medicineYoung adultcancer survivalLymphoma FollicularNon-Hodgkin lymphomaAgedHematologyWalesminimum clinical recommendations Non-Hodgkin lymphoma relative survival cancer survival follow upbusiness.industryCancerrelative survivalHematologyMiddle Agedmedicine.disease3. Good healthLymphoma[SDV] Life Sciences [q-bio]EuropeScotland030220 oncology & carcinogenesisFemaleLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphomaInternational Classification of Diseases for Oncology
researchProduct

Low incidence but poor prognosis of complicated coeliac disease: A retrospective multicentre study.

2013

Abstract Background Coeliac disease is a chronic enteropathy characterized by an increased mortality caused by its complications, mainly refractory coeliac disease, small bowel carcinoma and abdominal lymphoma. Aim of the study was to study the epidemiology of complications in patients with coeliac disease. Methods Retrospective multicenter case–control study based on collection of clinical and laboratory data. The incidence of complicated coeliac disease was studied among coeliac patients directly diagnosed in four Italian centres. Patients referred to these centres after a diagnosis of coeliac disease and/or complicated coeliac disease in other hospitals were therefore excluded. Results B…

AdultMalePediatricsmedicine.medical_specialtyPoor prognosisLymphoma B-CellSettore MED/09 - Medicina InternaComplicationsCELIAC DISEASEcomplicated coeliac diseaseKaplan-Meier EstimateGastroenterologyCoeliac diseaseNOCohort StudiesEnteropathy-Associated T-Cell LymphomaRefractoryCELIAC DISEASE; ComplicationsInternal medicineEpidemiologyIntestinal NeoplasmsIntestine SmallmedicinePrevalenceHumansAgedRetrospective StudiesHepatologybusiness.industryIncidence (epidemiology)IncidenceCarcinomaGastroenterologyCurve analysisnutritional and metabolic diseasesMiddle Agedmedicine.diseasePrognosisdigestive system diseasesLymphomaItalyAbdominal NeoplasmsCase-Control StudiesCohortFemalebusiness
researchProduct

Occupational exposure to immunologically active agents and risk for lymphoma: The European Epilymph case-control study

2013

Objectives: Allergies and asthma may be protective for the development of lymphoma. We evaluated whether occupational allergens that provoke immune reactivity and asthma through an IgE-mediated pathway are protective for lymphoma. Methods: The Epilymph study includes histologically or cytologically confirmed Hodgkin, B-cell, and T-cell lymphoma cases from six European countries (Spain, France, Germany, Italy, Ireland, and Czech Republic) recruited in 1998-2004. Controls were frequency matched to cases by age, gender, and study centre. Lifetime occupational exposure to seven high molecular weight (HMW) agents was evaluated through an asthma-specific job-exposure matrix. 2205 lymphoma cases a…

AdultMaleRiskCancer Researchmedicine.medical_specialtyAllergyLymphoma B-CellEpidemiologyHigh molecular weight exposuresLymphoma T-CellImmunoglobulin ELogistic regressionYoung Adultimmune system diseasesInternal medicinehemic and lymphatic diseasesEpidemiologyHypersensitivitymedicineHumansAsthma OccupationalYoung adultAgedAsthmabiologybusiness.industryCase-control studyAllergensImmunoglobulin EMiddle AgedOccupational exposuremedicine.diseaseHodgkin DiseaseLymphomaEuropeMolecular WeightOccupational DiseasesLogistic ModelsOncologyCase-Control StudiesImmunologybiology.proteinFemalebusinessCase–control
researchProduct

Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplant…

2001

We investigated whether a T cell-reduced allogeneic stem cell transplant (SCT) with minimal conditioning and subsequent donor lymphocyte infusions (DLI) could reduce the incidence and severity of GVHD while retaining stable engraftment. Five patients with hematological malignancies (three MM, one CLL, one Chediak-Higashi syndrome) were conditioned with TBI (200 cGy). One patient additionally received fludarabine (120 mg/m(2)). CsA and mofetyl-mycophenolate (MMF) were administered to prevent GVHD. All patients were grafted with >3 x 10(6)/kg highly purified CD34(+) cells together with 2 x 10(6)/kg CD3(+) cells (three patients) or 1 x 10(5)/kg CD3(+) cells (two patients). Quick hematopoietic …

AdultMaleTime FactorsLymphocyte TransfusionT-LymphocytesT cellLymphocyteChronic lymphocytic leukemiamedicine.medical_treatmentHematopoietic stem cell transplantationLymphocyte DepletionFatal OutcomemedicineHumansTransplantation HomologousTreatment FailureTransplantation ChimeraTransplantationbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedMycophenolic Acidmedicine.diseaseLeukemia Lymphocytic Chronic B-CellPeripheral stem cell transplantationFludarabineTransplantationmedicine.anatomical_structureHematologic NeoplasmsLymphocyte TransfusionImmunologyCyclosporineFemaleChediak-Higashi SyndromeMultiple MyelomabusinessImmunosuppressive AgentsVidarabineWhole-Body IrradiationFollow-Up Studiesmedicine.drugBone Marrow Transplantation
researchProduct

Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: An Italian, multicentre study

2009

Abstract Background/Aim Data on management and long-term follow-up of Helicobacter pylori -associated MALT-lymphoma in clinical practice are scanty. We evaluate the long-term efficacy of H. pylori eradication on low-grade MALT-lymphoma, and the efficacy of further therapies in refractory patients. Methods This study enrolled patients with stages I–II 1 MALT-lymphoma and H. pylori infection. H. pylori eradication was attempted in all patients. Patients with lymphoma persistence or progression following H. pylori treatments received further lymphoma treatments. Both 5-year and disease-free survivals were calculated. Results Sixty patients (stage I/II 1 : 50/10) were followed up for a median t…

AdultMaleVincristinemedicine.medical_specialtyCyclophosphamideSettore MED/12 - GASTROENTEROLOGIAGastric maltomamanagementKaplan-Meier EstimateGastroenterologyDisease-Free SurvivalHelicobacter InfectionsYoung AdultStomach Neoplasmsimmune system diseasesPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansYoung adultCyclophosphamideAgedRetrospective StudiesAged 80 and overHelicobacter pyloriHepatologybiologybusiness.industryGastroenterologyProton Pump InhibitorsMALT lymphomaRetrospective cohort studyLymphoma B-Cell Marginal ZoneMiddle AgedHelicobacter pyloribiology.organism_classificationmedicine.diseaseAnti-Bacterial AgentsLymphomaSurgeryItalyDoxorubicinVincristinePrednisoneFemalebusinessFollow-Up Studiesmedicine.drug
researchProduct

A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment

2011

Several chemokines/chemokine receptors such as CCR7, CXCR4 and CXCR5 attract chronic lymphocytic leukemia (CLL) cells to specific microenvironments. Here we have investigated whether the CX(3)CR1/CX(3)CL1 axis is involved in the interaction of CLL with their microenvironment. CLL cells from 52 patients expressed surface CX(3)CR1 and CX(3)CL1 and released constitutively soluble CX(3)CL1. One third of these were attracted in vitro by soluble CX(3)CL1. CX(3)CL1-induced phosphorylation of PI3K, Erk1/2, p38, Akt and Src was involved in induction of CLL chemotaxis. Leukemic B cells upregulated CXCR4 upon incubation with CX(3)CL1 and this was paralleled by increased chemotaxis to CXCL12. Akt phosp…

AdultMalechemokines; chronic lymphocytic leukemia (CLL); nurselike cells (NLCs); tumor microenvironmentCancer ResearchChemokineStromal cellChronic lymphocytic leukemiaCX3C Chemokine Receptor 1Antigens Differentiation MyelomonocyticchemokinesC-C chemokine receptor type 7Cell Communicationnurselike cells (NLCs)Chemokine receptorAntigens CDimmune system diseaseshemic and lymphatic diseaseschronic lymphocytic leukemia (CLL)medicineHumanstumor microenvironmentPhosphorylationAgedAged 80 and overTumor microenvironmentbiologyChemokine CX3CL1ChemistryChemotaxisHematologyMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-CellCX(3)CR1/CX(3)CL1 systemCX(3)CR1/CX(3)CL1 system; chronic lymphocytic leukemia.LeukemiaHaematopoiesisOncologychronic lymphocytic leukemia.Cancer researchbiology.proteinFemaleReceptors ChemokineLymph NodesProto-Oncogene Proteins c-aktSignal TransductionLeukemia
researchProduct

Recombinant human granulocyte-macrophage colony-stimulating factor induces secretion of autoinhibitory monokines by U-937 cells

1988

Colony-stimulating factors are required for survival proliferation, differentiation and functional activation of granulocytes, macrophages and their precursor cells. In the present report, however, we demonstrate antiproliferative activity of recombinant human (rh) granulocyte-macrophage colony-stimulating factor (GM-CSF) on monoblast cell line U-937 and provide evidence for the involvement of tumor necrosis factor alpha TNF-alpha and interleukin 1 beta (IL 1 beta) in its growth inhibitory action. GM-CSF (but not granulocyte CSF, G-CSF or macrophage CSF, M-CSF) suppressed DNA synthesis and self renewal of U-937 cells. Similarly, medium conditioned by U-937 cells in response to GM-CSF (GM-CS…

AdultMalemedicine.drug_classImmunologyMonoblastBiologyGranulocyteMonoclonal antibodyMonocytesColony-Stimulating FactorsTumor Cells CulturedmedicineHumansImmunology and AllergyMacrophageTumor Necrosis Factor-alphaMolecular biologyRecombinant ProteinsStimulation ChemicalGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureCell culturebiology.proteinTumor necrosis factor alphaLymphoma Large B-Cell DiffuseAntibodyCell DivisionInterleukin-1medicine.drugEuropean Journal of Immunology
researchProduct

Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autogra…

2011

Contains fulltext : 95663.pdf (Publisher’s version ) (Closed access) We present results of a phase 3 randomized trial of autografting in chronic lymphocytic leukemia versus observation for responding patients after first- or second-line treatment. The primary objective was to demonstrate that autografting improves the 5-year event-free survival (EFS) from 30% to 50%. There were 223 enrolled patients, 72% men and 28% women, 83% after first and 17% after second-line treatment. Binet stages were progressive A 13%, B 67%, C 20%; at randomization, 59% were in complete remission, and 41% in less than complete remission. Patients were randomized between autografting (n = 112) and observation (n = …

AdultMalemedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentChronic lymphocytic leukemiaImmunologyHematopoietic stem cell transplantationTransplantation AutologousBiochemistryGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSurvival rateAgedbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationTranslational research Immune Regulation [ONCOL 3]Cell BiologyHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyLeukemia Lymphocytic Chronic B-CellSurgeryFludarabineEuropeSurvival RateTransplantationTreatment OutcomeAlemtuzumabFemalebusinessmedicine.drug
researchProduct